Abstracts tagged "drug safety"

Abstract Number: 2553 • 2016 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Patients with Rheumatoid Arthritis Treated with Abatacept – Review of a Safety Database
H Yu, K Angelini, A Dominique and TA Simon, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Women are affected by RA 3–4 times more often than men. RA treatment choice during pregnancy can be a challenge for women to minimize…
Abstract Number: 1092 • 2015 ACR/ARHP Annual Meeting
Illicit Drug Use in US Adults with Chronic Low Back Pain: Nhanes 2009-2010
Anna Shmagel¹ and Robert Foley², ¹Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ²Renal Diseases and Hypertension, University of Minnesota, Minneapolis, MN
Background/Purpose: Addictive medications, such as opiates and benzodiazepines are frequently prescribed to patients with chronic low back pain (cLBP). Little is known about illicit drug…
Abstract Number: 2380 • 2013 ACR/ARHP Annual Meeting
Is Isoniazid Treatment For LTBI Safe For RA Patients With TNF Inhibitor Therapy?
Yoon-Kyoung Sung^1,2, Soo-Kyung Cho^1,2, Soyoung Won³, Jeeseon Shim³, Dam Kim⁴, Ji-Young Choi¹, Chan-Nam Son⁵, Chan-Bum Choi⁴, Tae-Hwan Kim⁶, Jae-Bum Jun⁶, Dae-Hyun Yoo⁶ and Sang-Cheol Bae^1,2, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁵Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Isoniazid (INH) is increasingly used in RA patients with evidence of latent tuberculosis infection (LTBI) for whom TNF inhibitor therapy is planned. The potential for…
Abstract Number: 1443 • 2013 ACR/ARHP Annual Meeting
Is The Risk Of Tumor Necrosis Factor Inhibitor-Induced Lupus The Same With Monoclonal Antibodies and Soluble Receptor? A Case/Non-Case Study In a Nationwide Pharmacovigilance Database
Guillaume Moulis¹, Agnès Sommet², Maryse Lapeyre-Mestre² and Jean-Louis Montastruc², ¹Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, France, ²Department of Clinical Pharmacology, Toulouse University Hospital, INSERM U1027, University of Toulouse, France, Toulouse, France
Background/Purpose: Albeit lupus occurring on each TNFi have been reported, no epidemiological study has been conducted to assess the link between lupus onset and each…
Abstract Number: 1041 • 2013 ACR/ARHP Annual Meeting
Non-Differential Reporting Of Myocardial Infarction To a National Observational Drug Safety Study Using Linked Data: Linkage Of The British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and The Myocardial Ischaemia National Audit Project
Audrey SL Low¹, Deborah P. Symmons^2,3, Mark Lunt², Louise K. Mercer², Christopher Gale^4,5, Kath Watson⁶, British Society for Rheumatology Biologics Registers (BSRBR) Control Centre Consortium¹, William G. Dixon⁷, Kimme L. Hyrich⁸ and On behalf of the BSRBR⁹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁴Division of Epidemiology, Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, United Kingdom, ⁵Department of Cardiology,York Teaching Hospital NHS Foundation Trust, York, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁷The University of Manchester, Manchester, United Kingdom, ⁸Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁹British Society for Rheumatology, London, United Kingdom
Background/Purpose: The BSRBR-RA was established to compare the long term safety of anti tumour necrosis factor (TNFi) drugs with non-biologic drugs (nbDMARD) in subjects with…
Abstract Number: 806 • 2013 ACR/ARHP Annual Meeting
Risk Of Cancer Recurrence Or New Tumors In RA Patients With Prior Malignancies Treated With Various Biologic Agents
Anja Strangfeld¹, Dagmar Pattloch², Peter Herzer³, Edmund Edelmann⁴, Silke Zinke⁵, Martin Aringer⁶, Joachim Listing⁷ and Angela Zink⁸, ¹Programme Area Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ²Programm Area Epidemiologiy, German Rheumatism Research Center, Berlin, Berlin, Germany, ³University of Munich, Munich, Germany, ⁴Rheumatologist, Bad Aibling, Germany, ⁵Rheumatological Office, Berlin, Germany, ⁶Rheumatology, Medicine III, University Clinical Center Technical University of Dresden, Dresden, Germany, ⁷German Rheumatism Research Center, Berlin, Germany, ⁸German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: If patients with rheumatoid arthritis (RA) have a history of malignancy, the choice of treatment is an important clinical question. The aim is to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].